Abstract 1459P
Background
KN046 is a novel bispecific antibody that inhibits both PD-L1/PD1 and CTLA-4/CD80/CD86 pathways. Previous phase I (KN046-CHN-001, NCT03733951) and phase II (KN046-201, NCT03838848) trials showed promising anti-tumor effects of KN046 in non-small cell lung cancer (NSCLC) patients who had failed prior immune checkpoint inhibitor(s) (ICIs) therapy. We present the efficacy and safety outcomes of KN046 in this population from KN046-CHN-001 and Cohort C of KN046-201.
Methods
KN046-CHN-001 and KN046-201 assessed the efficacy, safety and tolerability of KN046 in NSCLC. Eligible patients had NSCLC that progressed after ICI(s) and platinum-based chemotherapy. Patients with EGFR mutation and/or ALK translocation were excluded. All patients received KN046 (26 at 5 mg/kg Q2W, 2 at 5 mg/kg Q3W, 2 at 300mg Q3W and 1 at 3 mg/kg Q2W) by IV infusion. The primary endpoints were confirmed ORR by RECIST version 1.1 (KN046-201) and safety (KN046-CHN-001).
Results
Between April 19, 2019 and July 13, 2020, 31 pts with metastatic NSCLC who failed ICI(s) and platinum-based chemotherapy were enrolled. At the data cutoff of July 30, 2022 for KN046-201 and August 31, 2021 for KN046-CHN-001, the median follow-up was 25.0months (95% CI, 24.4, NE). Among all 31 pts, the ORR was 3.2% (1/31, 95% CI, 0.1, 16.7%), disease control rate (DCR) was 38.7% (12/31, 95% CI, 21.8, 57.8%), clinical benefit rate (CBR) was16.1% (5/31, 95% CI, 5.5, 33.7%). Median progression-free survival (mPFS) was 2.8 months (95% CI, 1.8, 3.7) and median overall survival (mOS) was 13.3 months (95% CI, 6.5, 17.5). 7(22.6%) out of the 31 subjects had experienced treatment-related adverse event (TRAE) at grade 3 or higher levels. Commonly reported TRAEs of grade 3 or higher were anemia (9.7%), febrile neutropenia (3.2%), fatigue (3.2%).
Conclusions
KN046 was well tolerated and demonstrated encouraging OS benefit in NSCLC patients who had failed prior ICI(s) therapy. Further study is warranted to confirm the clinical results.
Clinical trial identification
KN046-201, NCT 03838848; KN046-CHN-001, NCT03733951.
Editorial acknowledgement
Alphamab Biopharma, Inc would like to thank the patients, investigators and site staff for their participation in this study.
Legal entity responsible for the study
Jiangsu Alphamab Biopharmaceuticals, Co., Ltd.
Funding
Jiangsu Alphamab Biopharmaceuticals, Co., Ltd.
Disclosure
C. Zhou: Financial Interests, Personal, Invited Speaker, Honoraria: Eli Lily, Roche, Sanofi, Qilu Pharma, Hengrui, Innovent Biologics, C-Stone, Luye Pharma, TopAlliance Biosciences Inc; Financial Interests, Personal, Invited Speaker, BI: BI; Financial Interests, Personal, Invited Speaker, MSD: MSD; Financial Interests, Personal, Advisory Board, Advisor: Amoy Diagnostics. All other authors have declared no conflicts of interest.
Resources from the same session
1432P - Tumor stage shift in lung cancer during the COVID-19 pandemic: A real-world data study of the Network Oncology Registry
Presenter: Anja Thronicke
Session: Poster session 20
1433P - CNS efficacy of atezolizumab, bevacizumab, carboplatin and paclitaxel in patients with non-small cell lung cancer and actionable mutations
Presenter: Marcus Rathbone
Session: Poster session 20
1434P - Machine learning features derived from spatial interaction of immune cell families are associated with survival in NSCLC patients post-immunotherapy
Presenter: sara arabyarmohammadi
Session: Poster session 20
1435P - Clinical and molecular study with digital support of advanced non-small cell lung cancer patients: SNF-CLIMEDIN, a prospective randomized Hellenic Cooperative Oncology Group (HeCOG) study: Interim analysis
Presenter: Helena Linardou
Session: Poster session 20
1436P - Prospective study utilizing ctDNA genome-wide copy number variations for longitudinal monitoring of patients with advanced non-small cell lung cancer
Presenter: Pengkai Han
Session: Poster session 20
1437P - Clinical and economic burden of tissue re-biopsy (TRB) vs. tissue followed by liquid biopsy (TFLB) in metastatic non-small cell lung cancer (mNSCLC) patients
Presenter: Nicole Engel-Nitz
Session: Poster session 20
1438P - Cemiplimab for advanced non-small cell lung cancer: Squamous subgroup analysis for EMPOWER-Lung 1 and 3
Presenter: Tamta Makharadze
Session: Poster session 20
1440P - Final top-line results of the BGBC008 phase II, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in second-line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571)
Presenter: Enriqueta Felip
Session: Poster session 20
1441P - Atezolizumab and bevacizumab (atezo + bev) ± radiotherapy (RT) vs docetaxel (doc) in checkpoint inhibitor (CPI)–experienced metastatic NSCLC (mNSCLC): Results from the phase Ib/II MORPHEUS-lung study
Presenter: Francois Ghiringhelli
Session: Poster session 20